✦ LIBER ✦

P-955 Clinicopathological features and efficacy of gefitinib in patients with non-small cell lung cancer (NSCLC) — Comparison between adenocarcinoma and non-adenocarcinoma

✍ Scribed by Kawano, Y.; Kashii, T.; Katayama, H.; Hasegawa, Y.; Tokunaga, S.; Sumitani, M.; Takeda, K.; Takifuji, N.; Nakajima, R.; Tada, H.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy and tolerability of gefitinib i

✍ Cappuzzo, F; Bartolini, S; Ceresoli, G L; Tamberi, S; Spreafico, A; Lombardo, L; 📂 Article 📅 2004 🏛 Nature Publishing Group 🌐 English ⚖ 85 KB

Comparison of adverse events and efficac

✍ Tsukasa Yoshida, Kazuhiko Yamada, Koichi Azuma, Akihiko Kawahara, Hideyuki Abe, 📂 Article 📅 2012 🏛 Springer US 🌐 English ⚖ 225 KB

Efficacy of gefitinib for non-adenocarci

✍ Takehito Shukuya; Toshiaki Takahashi; Rieko Kaira; Akira Ono; Yukiko Nakamura; A 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 232 KB

A phase I trial of gefitinib and nimotuz

✍ Kim, Se Hyun; Shim, Hyo Sup; Cho, Jaeho; Jeong, Jae Heon; Kim, Sun Mi; Hong, Yun 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 275 KB

PCN7 THE LIFETIME COST OF GEFITINIB (“IR

✍ A Haiderali; W Chin 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 63 KB

590 Induction of cytotoxic T cells (CTL)

✍ Yoshino, I.; Takenoyama, M.; Hanagiri, T.; Yoshimatsu, T.; Imabayashi, S.; Eifuk 📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 155 KB